Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
In part 2 of this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed about the products in the works at Sanofi.
Rachele Berria is global vice president and head of medical affairs at Sanofi in Bridgewater, New Jersey.
Transcript of this video segment:
Freed: Sanofi has come out with some unique products from very few to all of a sudden over a short of period of time an SGLT2, SGLT1s, new insulins, so you’ve been very active in the field. What’s in your pipeline? You must have something.
Berria: Absolutely. So, we talked about Zynquista. We also have a weekly GLP-1 receptor agonist. We’re working and very committed to a dual co-agonist both GLP-1 and glucagon agonist. We have a partnership that is called Onduo, that brings the best of two worlds, the scientific expertise of Sanofi and the technological expertise of Google Verily. And we let them run and play, but they will have a fundamental role because we believe that medicines are important but as you’ve said before Steve, medicines are not the only thing that patients need and the behavioral component is equally important for them to be really taking their meds and be persistent in taking these medications. And Onduo is doing a lot of that with already some pilot projects that are ongoing with the virtual diabetes clinics.
Freed: So, one of the combinations that’s been very successful is the SGLT2 and GLP-1. Do you have something — and one is an injectable and one is not, but as far as combining them is there something in the pipeline that’s combining those two?
Berria: We’re doing even better than that. We have a fixed-ratio combination called Soliqua 100/33, a basal insulin and a GLP-1. There’s not that much data here at the ADA. There’s a few abstracts. One, that I’m really proud about showing that it is equally effective in Hispanic and Non-Hispanic patients that were also starting Solique 100/33 on a background of SGLT2 inhibitors and its oral medications which are becoming widespread, so that will be presented probably at the next Scientific Sessions. And also, since we’re so committed to patients that are of various races and ethnicities, we started recruiting for a study that is solely dedicated to them and that will in fact include Asians, African-Americans, and Hispanics where we are testing Soliqua 100/33 versus glargine 100 which is Lantus.